
Frontline Amivantamab Plus Lazertinib Significantly Reduces Mortality in EGFR-Mutant Advanced NSCLC
The combination of amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) significantly improved overall survival (OS) vs osimertinib (Tagrisso) when used as frontline treatment in patients with EGFR-mutant non–small cell lung cancer (NSCLC), according to …